Www.nasa.gov Michelle P. Lewis Patent License Manager Rapid Detection of the Varicella Zoster Virus (VZV) in Saliva Samples Johnson Space Center Advanced.

Slides:



Advertisements
Similar presentations
Serological tests (Antigen antibody interactions)
Advertisements

ExpressDetect® Mitch Sanders, CEO. June 2009 ECI Biotech  ECI Biotech is a premier developer of ExpressDetect® Diagnostics.  ExpressDetect ® Diagnostics.
PULSE IMAGING, Inc. Company Overview 11/12/08 A World Without Skin Biopsies NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM.
Immune Testing.
Design of Health Technologies lecture 12 John Canny 10/17/05.
What we ask in a ROI What it is? Is it related to another invention? Who contributed to making the invention? Who paid for the research? When invention.
Karen LeVert, CEO Southeast TechInventures (STI) Research Triangle Park, NC x100 University.
Avian Influenza H5N1 Reactive Antibodies BA 468x Technology Commercialization.

National Aeronautics and Space Administration Explorers’ Guide to the Solar System 1 National Aeronautics and Space Administration
Enzyme-Linked Immunosorbent Assay ELISA 1Dr. Nikhat Siddiq.
Adult Immunization 2010 Herpes Zoster (Shingles) Segment This material is in the public domain This information is valid as of May 25, 2010.
Experiment ten To detect the HBsAg with ELISA. ELISA Enzyme linked immunosorbent assay is a normal and simple means to detect the Ag and Ab of HBV and.
National Health and Medical Research Council NHMRC – EU Collaborative Research Grants Scheme Dr Nick Johnson Research Programs Branch NHMRC.
UCLA Nanoscale Measurement System March 18, 2005 Nanoscale Measurement System Non-confidential summary of UCLA technology available for licensing, Case.
Varicella-zoster The disease and Panbio product training.
Basic Immunologic Procedures
1 OraQuick ® ADVANCE ™ HIV 1/2 Antibody Test (Oral Fluid Specimen Type) Blood Products Advisory Committee Meeting March 10, 2006.
Enzyme-Linked Immunosorbent Assay
Partnering with the National Institute of Allergy and Infectious Diseases Michael R. Mowatt, Ph.D. Director, Technology Transfer and Intellectual Property.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
UARC Intellectual Property Management Burney Le Boeuf Director, Aligned Research Program of UARC Professor Emeritus UC Santa Cruz November 12, 2009.
Duane L. Pierson, Ph.D. NASA Johnson Space Center Houston, Texas Duane L. Pierson, Ph.D. NASA Johnson Space Center Houston, Texas.
Rapid Detection of Varicella Zoster Virus
Nanoscience and Health Research. The role of nanotechnology in: Fighting disease causing organisms. Developing medical devices. Faster diagnoses.
ELISA Assay. What Is It? Enzyme immunoassay (EIA) is a test used to detect and quantify specific antigen-eliciting molecules involved in biological processes,
Navigating the University Technology Transfer August 23, 2012 Christopher Moulding Sr. Manager, Technology Advancement and Licensing I’ve got an idea…now.
A Novel Approach to Lactate Sensing
Ex. 27: HIV ELISA, AIDS Diagnostic Tool. Human Immuno- deficiency Virus (HIV) First diagnosed in 1981 Over 20 million deaths worldwide, over a half million.
contact us at: Jerry Miller Director, Intellectual Asset Management Intellectual Property (IP) Management Group Decision Making Using Market.
School of Biomedical Engineering, Science & Health Systems V 1.0 SD [020214] The sensor market is one of the fastest.
Innovation Acceleration Partner Fellows Program Approaches to Improving Commercialization and Innovation National Science Foundation Partner for Innovation.
Enzyme Linked Immunosorbent Assay. Purpose of ELISA  To detect antibodies in your blood or urine.  To see if you have been exposed to a disease.
Enter the Title of Your Presentation Lead Inventors Name Other Inventors Name Purpose: Enter why you are coming to patent committee (initial filing, PCT,
Office of Technology Development Case No. ________ CONFIDENTIAL Intellectual Property Committee Presentation Inventor(s) Invention Title Presentation Guidelines:
Human Immunodeficiency Virus (HIV) First diagnosed in 1981 Over 20 million deaths worldwide, over a half million in the United States Over 40 million currently.
Enzyme linked immunosorbent assay
“28,424 cases of Ebola and still counting—what have we learned
THE PROBLEM: CURRENT CONTINUOUS GLUCOSE MONITORS (CGM) ARE INVASIVE Continuous glucose monitoring is critical for some diabetics and very advantageous.
National Aeronautics and Space Administration N A S A G o d d a r d S p a c e F l i g h t C e n t e r 1 p r e s e n t e d a t.
OMICS international Contact us at: OMICS International through its Open Access Initiative is committed to make genuine and.
Transmission of Disease How do we get sick?. In order to catch an infectious disease, all four conditions listed below must occur  There is the presence.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
Laboratory #2: ELISA Immuno Explorer
ELISA Enzyme-linked Immunosorbant Assay Detects the presence of minutes quantities of either an antibody or an antigen Important diagnostic tool in many.
Review of Research-Related Agreements Between Academic Institutions and Other Entities. Manoja Ratnayake Lecamwasam, PhD Intellectual Property and Innovation.
[Business/Concept Name] [Presenter, Key Personnel] ***Remember as you draft your slides that there is a hard 12 minute stop on your presentation***
Innovation in Pediatric Medical Devices: Thinking Outside The Box Gwenyth Fischer University of Minnesota Masonic Children’s Hospital.
2016/6/24 All rights Reserved. Copyright (c) 2008 The University of Tokyo University Corporate Relations, Intellectual Property Management and Technology.
ELISA (Enzyme-Linked Immunosorbent Assay)
15283 New Sensitive and Specific Rapid HSV-2 Antibody Test Objective To describe the performance and uses of a new HSV-2 specific serological rapid test,
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 HIV Diagnostics Market size.
Europe clinical laboratory services market set to exceed $62 bn by 2024
Detection of Infectious diseases Using Antibodies
Haemagglutination assay
Universities and the Commercial World
Lanarkshire Stroke Care – Monitors Martin Whitehead
Protecting and exploiting research results at Newcastle University Geraint Lewis – Business Development Manager, Research and Enterprise Services
Labeled Immunoassays.
ELISA.
Amy Johnson Director & Entrepreneur-in-Residence.
Differential diagnosis of pandemic (H1N1) 2009 infection by detection of haemagglutinin with an enzyme-linked immunoassay  Q. Yuan, X.-D. Cheng, B.-C.
ELISA Immuno ExlorerTM HIV/AIDS Diagnostic Tool
Mechanism of action of maturation inhibitors of HIV-1
ELISA Immuno ExlorerTM HIV/AIDS Diagnostic Tool
Wednesday, November 28, 2018| 8:30-9:30 a. m
A Real World Application of the Scientific Method
Experimental Systems and Methods
Varicella Vaccine Efficacy Estimates
Presentation transcript:

Michelle P. Lewis Patent License Manager Rapid Detection of the Varicella Zoster Virus (VZV) in Saliva Samples Johnson Space Center Advanced Planning Office National Aeronautics and Space Administration

National Aeronautics and Space Administration Technology Summary VZV Testing System – Method for detecting an active varicella zoster virus (VZV) by obtaining a saliva sample. – Uses a sandwich assay of two antibodies, one attached to magnetic particles and other to an enzyme, horseradish peroxidase (HRP). – Sample is applied to a micro-column that contains the magnetic particles immobilized by a magnet. – A solution of luminol, is washed through the device; as it reacts with the HRP, light is emitted to indicate the VZV presence. – Allows for rapid testing in 15 minutes or less in a doctor’s office. – Rapid, simple, non-invasive, sensitive, inexpensive, point-of-care testing (POCT) diagnostic device. Applications – Potential applicability for testing of saliva for other infectious agents.

National Aeronautics and Space Administration Technology Status Associated Intellectual Property – Provisional patent application (61/087,045) filed on 08/07/2008. – The University of Colorado filed a foreign patent (PCT/US2009/052992) on 8/6/2009. – NASA JSC and the University of Colorado have a Joint Ownership Agreement – Available for licensing within the U.S. Development Status – Prototype exists and proof of concept has been demonstrated. – Needs regulatory approval and clinical trials. Market/Opportunity for Technology – 1 million cases of shingles yearly in the U.S. is estimated by the Centers for Disease Control and Prevention – Almost half of shingles cases occur in adults 60 years of age. – Overall POCT market is forecasted to be $18.7 billion by 2011

National Aeronautics and Space Administration Contacts NASA JSC Advanced Planning Office Michelle P. Lewis Patent License Manager (281) Website: Inventors Robert E. Harding Randall J. Cohrs Donald H. Gilden Duane L. Pierson Satish K. Mehta